Microbiota Therapeutics – Additional (non-C. difficile) Treatment Areas


The only indication for which the FDA allows clinical use of IMT is C. difficile infection that is not responding to standard therapies. All other indications require formal FDA approval for use of IMT as an investigational new drug. 

There are many ongoing clinical trials on intestinal microbiota transplantation and various diseases.

Inflammatory Bowel Disease (IBD) – Ulcerative Colitis and Crohn’s Colitis

 

IBD results from inappropriate immune response against the gut microbiota. Several placebo-controlled studies suggest that there is a subset of patients who may benefit from IMT. Patients with these diseases do have an altered composition of microbiota, although it is not known whether this is cause or consequence of the disease. We are working to understand the role of microbiota in these conditions by using Microbiota Therapeutics and microbiome analyses.

© 2020 Regents of the University of Minnesota. All rights reserved. The University of Minnesota is an equal opportunity educator and employer. Privacy Statement